Expertise in
22
conditions

Dr. Muzaffar H. Qazilbash

Hematology
UT MD Anderson Cancer Center
1515 Holcombe Blvd, 
Houston, TX 
Offers Telehealth
35 Years of Experience
Expertise in
22
conditions
UT MD Anderson Cancer Center
1515 Holcombe Blvd, 
Houston, TX 

Overview

Muzaffar Qazilbash is a Hematologist practicing medicine in Houston, Texas. He has been practicing medicine for over 35 years.

Dr. Qazilbash is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Acute Myeloid Leukemia (AML), Graft Versus Host Disease (GvHD), Bone Marrow Transplant, and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 284 peer reviewed articles and participating in 6 clinical trials.

Specialties

Hematology

Licenses

Internal Medicine in TX

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HMSA
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
QualChoice
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

UT MD Anderson Cancer Center
1515 Holcombe Blvd, Houston, TX 77030

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Daratumumab-Based Maintenance in Patients With Relapsed Multiple Myeloma After Salvage Autologous Stem Cell Transplantation
Daratumumab-Based Maintenance in Patients With Relapsed Multiple Myeloma After Salvage Autologous Stem Cell Transplantation
Enrollment Status: Terminated
Publish Date: April 24, 2026
Intervention Type: Biological
Study Drug: Daratumumab
Study Phase: Phase 2
S1803, Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients With Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
S1803, Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients With Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
Enrollment Status: Active_not_recruiting
Publish Date: September 15, 2025
Intervention Type: Drug
Study Drugs: Lenalidomide, Daratumumab/rHuPH20
Study Phase: Phase 3
A Phase 3 Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of AB-205 Plus Standard of Care Versus Placebo Plus Standard of Care in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT) (E-CELERATE)
A Phase 3 Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of AB-205 Plus Standard of Care Versus Placebo Plus Standard of Care in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT) (E-CELERATE)
Enrollment Status: Terminated
Publish Date: February 04, 2025
Intervention Type: Other, Biological
Study Drug: AB-205
Study Phase: Phase 3
A Phase 1 Study to Evaluate the Safety, Proliferation and Persistence of GEN-011, an Autologous Adoptive Cell Therapy Targeting Neoantigens in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Proliferation and Persistence of GEN-011, an Autologous Adoptive Cell Therapy Targeting Neoantigens in Solid Tumors
Enrollment Status: Terminated
Publish Date: July 15, 2022
Intervention Type: Drug, Biological
Study Drugs: IL-2, Fludarabine, Cyclophosphamide
Study Phase: Phase 1
A Phase 1, Open Label, Non-randomized, Multi-Center Trial of AB-205 in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation
A Phase 1, Open Label, Non-randomized, Multi-Center Trial of AB-205 in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation
Enrollment Status: Completed
Publish Date: March 03, 2022
Intervention Type: Biological
Study Drug: AB-205 Engineered Human Umbilical Vein Endothelial Cells
Study Phase: Phase 1
View 4 Less Clinical Trials

284 Total Publications

D-VRD vs. D-KRD induction in transplant-eligible multiple myeloma: a real-world comparison.
D-VRD vs. D-KRD induction in transplant-eligible multiple myeloma: a real-world comparison.
Journal: Leukemia & lymphoma
Published: June 26, 2026
Similar Doctors
Expertise in
30
conditions
Expertise in
30
conditions
Referral may be required

University Of Texas MD Anderson Cancer Center

1515 Holcombe Blvd Unit 428, 
Houston, TX 
 (0.3 miles away)
713-792-2121
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Gautam Borthakur is a Hematologist practicing medicine in Houston, Texas. Dr. Borthakur is highly rated in 30 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Expertise in
34
conditions
Expertise in
34
conditions
Referral may be required

Office

1400 Holcombe Blvd Unit 428, 
Houston, TX 
 (0.3 miles away)
713-792-2813
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Naveen Pemmaraju is a Hematologist practicing medicine in Houston, Texas. Dr. Pemmaraju is highly rated in 34 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Myelofibrosis, Bone Marrow Aspiration, and Bone Marrow Transplant.

Expertise in
33
conditions
Expertise in
33
conditions
Referral may be required

University Of Texas MD Anderson Cancer Center

1515 Holcombe Blvd Unit 428, 
Houston, TX 
 (0.3 miles away)
713-792-6161
Languages Spoken:
English
See accepted insurances

Nitin Jain is a Hematologist practicing medicine in Houston, Texas. Dr. Jain is highly rated in 33 conditions, according to our data. His clinical expertise encompasses Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Frequently Asked Questions about Dr. Muzaffar H. Qazilbash

How do I make an appointment with Dr. Muzaffar H. Qazilbash?

You can book an appointment with Dr. Muzaffar H. Qazilbash by calling their office at 713-792-6100. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Muzaffar H. Qazilbash a top-rated expert for Multiple Myeloma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Muzaffar H. Qazilbash is classified as an Elite expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Muzaffar H. Qazilbash specialize in?

While Dr. Muzaffar H. Qazilbash is a Hematology, they have specific expertise in Multiple Myeloma, Bone Marrow Transplant, and Acute Myeloid Leukemia (AML). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Muzaffar H. Qazilbash participate in research or clinical trials?

Yes. Dr. Muzaffar H. Qazilbash has published 284 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Dr. Muzaffar H. Qazilbash's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Muzaffar H. Qazilbash accept my insurance?

Dr. Muzaffar H. Qazilbash accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 713-792-6100 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Qazilbash's expertise for a condition
ConditionClose
View All 10 Distinguished Conditions
View All 10 Advanced Conditions
View All 28 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile